RxDoctor Payments Data

Richard Markowitz, MD

Internal Medicine · Hewlett, NYNPI 1063414282

Payments from drug & device makers

$1,779in general payments, 2019–2025

Across 49 payments — averaging $36.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$475
  • AstraZeneca$433
  • Bayer$232
  • Johnson & Johnson$114
  • Boston Scientific$113
  • Phathom Pharmaceuticals, Inc.$105
  • plus $306 from 10 others

What the payments were for

  • Food & beverage$1,779100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,779 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$121,286
Medicare patients
378
Services billed
1,498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol32$38,816
RybelsusSemaglutide16$36,430
XareltoRivaroxaban30$35,804
JardianceEmpagliflozin16$29,778
JanuviaSitagliptin Phosphate29$28,619
Janumet XrSitagliptin Phos/Metformin Hcl29$23,789
EliquisApixaban27$22,970
MounjaroTirzepatide14$19,852
OzempicSemaglutide16$14,125
JanumetSitagliptin Phos/Metformin Hcl11$12,611
Spiriva RespimatTiotropium Bromide11$7,263
EdarbyclorAzilsartan Med/Chlorthalidone16$5,725
SynthroidLevothyroxine Sodium90$5,041
Levothyroxine Sodium189$3,659
Atorvastatin Calcium383$3,484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$475$50,55532 claims
AstraZenecaFarxiga$433$38,81632 claims
Johnson & JohnsonXarelto$114$35,80430 claims
AbbVieSynthroid$77$5,04190 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Hewlett

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →